About The Study: This cross-sectional study of patients with de novo metastatic breast cancer (dnMBC) found racial and ethnic disparities in disease presentation and inequities in timely treatment for dnMBC across subtypes, emphasizing the need for tailored interventions to improve care delivery and outcomes. De novo metastatic breast cancer, defined as the presence of distant metastases at initial diagnosis, accounts for only 5.4% to 10.0% of new cases but disproportionately contributes to breast cancer mortality in the U.S.

About The Study: In this cross-sectional study of Chinese youths, longer breastfeeding duration was not associated with cognitive performance in the unadjusted model but was associated with better cognitive performance after adjustment for socioeconomic status. Longer breastfeeding was more common among families with low socioeconomic status. Continued policy support, such as extended maternity leave and workplace lactation accommodations, may be warranted alongside further longitudinal research.

The research group of Prof. Sanjiv Luther at the Department of Immunobiology, University of Lausanne, has discovered that a fibroblast subtype is essential for coordinating certain immune cells within lymph nodes. This represents another step forward in understanding how the immune system functions in response to infections or cancer.

A new analysis by researchers at The University of Texas MD Anderson Cancer Center demonstrates that combination therapy consisting of fludarabine, cytarabine and G-CSF (FLAG) plus gemtuzumab ozogamicin (GO) or idarubicin (IDA) continues to deliver strong long-term outcomes for patients with core-binding factor acute myeloid leukemia (CBF-AML), a subtype of the disease involving a chromosomal rearrangement.

The EU project PANORAMIX, coordinated by DTU, indicates that mixtures of man-made chemicals present in human blood or breast milk may affect reproductive health and child development - even when individual substances are within accepted safety levels.

The Keck School of Medicine of USC and Keck Medicine of USC have launched collaborations with Tempus AI, Inc., a technology company at the forefront of applying AI to precision medicine, to integrate clinical care, clinical trials and research through a unified framework. The new framework intends to create an ongoing cycle of learning between patient care and research, with a primary goal of improving outcomes for the more than 1.5 million annual patient visits to Keck Medicine of USC hospitals and clinics. It is designed to promote more personalized and precise care to patients across the Keck Medicine of USC health system with tailored recommendations informed by large-scale clinical data. At the same time, it seeks to use clinical data to inform and accelerate research to develop innovative therapies and algorithms that may translate for public benefit. At the heart of the USC -Tempus collaboration is the pioneering research and patient care delivered by the USC Norris Comprehensive Cancer Center. The strategic undertaking is anchored by four key pillars. These include clinical testing, which can enable detailed molecular and genetic profiling at the patient level; clinical trials matching, which automatically matches eligible patients with novel targeted therapies; clinical care gap pathways, which uses AI-driven insights to promote evidence-based patient care; and research collaboration and co-development, aimed at moving academic discoveries into real-world diagnostics and treatments. Together, these elements have the potential to create an integrated ecosystem that connects patient care and research. This collaboration will start with a focus on precision oncology, with the intension of creating a proven model for integrating care and research, that can then be extended over time to other specialties, including cardiology, neurology and radiology.